|
| 37827694 | EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. | Ann Rheum Dis | 2024 |
| 38019168 | Patient clusters identified by machine learning from a pooled analysis of the clinical development programme of secukinumab in psoriatic arthritis, ankylosing spondylitis and psoriatic arthritis with axial manifestations. | Clin Exp Rheumatol | 2024 |
| 38073017 | Different Immunologic Profiles Are Associated With Distinct Clinical Phenotypes in Longitudinally Observed Patients With Systemic Lupus Erythematosus. | Arthritis Rheumatol | 2024 |
| 37691498 | Derivation and Internal Validation of a Disease-Specific Cardiovascular Risk Prediction Model for Patients With Psoriatic Arthritis and Psoriasis. | Arthritis Rheumatol | 2024 |
| 34344704 | Response to: Correspondence on "New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE" by Pons-Estel <i>et al</i>. | Ann Rheum Dis | 2023 |
| 37527862 | Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting. | J Rheumatol | 2023 |
| 37527861 | Proceedings of the GRAPPA 2022 Executive Retreat. | J Rheumatol | 2023 |
| 37555242 | Derivation of a Multivariable Psoriatic Arthritis Risk Estimation Tool (PRESTO): A Step Towards Prevention. | Arthritis Rheumatol | 2023 |
| 37657794 | Psoriatic Arthritis and COVID-19: Patient Perspectives in a Large Psoriatic Arthritis Cohort. | J Rheumatol | 2023 |
| 37792508 | Incidence and predictors of demyelinating disease in spondyloarthritis: data from a longitudinal cohort study. | Rheumatology (Oxford) | 2023 |
| 37945284 | Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial. | RMD Open | 2023 |
| 37645684 | The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2. | Ther Adv Musculoskelet Dis | 2023 |
| 37873414 | GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets. | medRxiv | 2023 |
| 37819505 | Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study. | Rheumatol Ther | 2023 |
| 35789257 | Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE. | Rheumatology (Oxford) | 2023 |
| 35487679 | Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' | Ann Rheum Dis | 2023 |
| 37125665 | Correspondence on "relationship between the EULAR/ACR classification criteria and organ damage in systemic lupus erythematosus" by Chi Chiu Mok et al. | Lupus | 2023 |
| 36958766 | Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension. | RMD Open | 2023 |
| 37459273 | Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort. | Arthritis Rheumatol | 2023 |
| 37419627 | Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 Annual Meeting. | J Rheumatol | 2023 |
| 37419621 | Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group. | J Rheumatol | 2023 |
| 37419620 | Project Highlights From the GRAPPA 2022 Annual Meeting: Education Initiatives and Axial Involvement in Psoriatic Arthritis. | J Rheumatol | 2023 |
| 37085289 | Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes. | Ann Rheum Dis | 2023 |
| 37148474 | Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis. | Rheumatol Ther | 2023 |
| 37208152 | Systemic Lupus Erythematosus Women with Lupus Nephritis in Pregnancy Therapeutic Challenge (SWITCH): The Systemic Lupus International Collaborating Clinics experience. | Ann Rheum Dis | 2023 |
| 37094983 | Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study. | RMD Open | 2023 |
| 37463128 | Prediction of Psoriatic Arthritis in Patients With Psoriasis Using DNA Methylation Profiles. | Arthritis Rheumatol | 2023 |
| 36521913 | Real-World Retention and Clinical Effectiveness of Secukinumab for Psoriatic Arthritis: Results From the Canadian Spondyloarthritis Research Network. | J Rheumatol | 2023 |
| 36651668 | Genetics of osteonecrosis in children and adults with systemic lupus erythematosus. | Rheumatology (Oxford) | 2023 |
| 36917505 | Cardiac Magnetic Resonance Imaging T1 and T2 Mapping in Systemic Lupus Erythematosus in Relation to Antimalarial Treatment. | J Thorac Imaging | 2023 |
| 36691838 | Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate Modeling. | Arthritis Care Res (Hoboken) | 2023 |
| 36916720 | Genetics of longitudinal kidney function in children and adults with systemic lupus erythematosus. | Rheumatology (Oxford) | 2023 |
| 36913183 | Persistence of Biologics in the Treatment of Psoriatic Arthritis: Data From a Large Hospital-Based Longitudinal Cohort. | Arthritis Care Res (Hoboken) | 2023 |
| 36777695 | Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib. | Ther Adv Musculoskelet Dis | 2023 |
| 36642434 | Real-World Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results From the Canadian Spondyloarthritis Research Network. | J Rheumatol | 2023 |
| 36503376 | Improving measures of disease activity in systemic lupus erythematosus. | Expert Rev Clin Immunol | 2023 |
| 36495881 | Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). | Lancet | 2023 |
| 36728467 | Cardiac Magnetic Resonance Imaging and Clinical Follow-up in Antimalarial-induced Cardiomyopathy in Patients With Systemic Lupus Erythematosus. | J Thorac Imaging | 2023 |
| 36243416 | Isolated Neutropenia in Systemic Lupus Erythematosus. | J Rheumatol | 2023 |
| 36243407 | Sex Effect in Psoriatic Arthritis. | J Rheumatol | 2023 |
| 36379576 | Musculoskeletal Surgery in Psoriatic Arthritis: Prevalence and Risk Factors. | J Rheumatol | 2023 |
| 36319012 | Evaluating the Threshold Score for Classification of Systemic Lupus Erythematosus Using the EULAR/ACR Criteria. | J Rheumatol | 2023 |
| 36318999 | Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. | J Rheumatol | 2023 |
| 34962100 | Evaluating the Construct of Damage in Systemic Lupus Erythematosus. | Arthritis Care Res (Hoboken) | 2023 |
| 33152181 | Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. | Arthritis Care Res (Hoboken) | 2022 |
| 35649547 | Effectiveness of Disease-Modifying Antirheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort. | J Rheumatol | 2022 |
| 35606663 | Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials. | Rheumatol Ther | 2022 |
| 35428720 | Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis. | J Rheumatol | 2022 |
| 35428718 | Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial. | J Rheumatol | 2022 |
| 35716465 | Outcomes following antimalarial withdrawal in patients with quiescent systemic lupus erythematosus. | Semin Arthritis Rheum | 2022 |